

MusclePharm Corp  
Form 8-K  
December 19, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**December 15, 2016**

**Date of report (date of earliest event reported)**

**MusclePharm Corporation**

**(Exact name of registrant as specified in its charter)**

<b>Nevada</b>	<b>000-53166</b>	<b>77-0664193</b>
<b>(State or other jurisdictions of</b>	<b>(Commission</b>	<b>(I.R.S.</b>
<b>incorporation or organization)</b>	<b>File Number)</b>	<b>Employer</b>
		<b>Identification</b>
		<b>Nos.)</b>

**4721 Ironton Street, Building A**

**Denver, Colorado 80239**

**(Address of principal executive offices) (Zip Code)**

**(303) 396-6100**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 15, 2016, Stacey Jenkins resigned from the board of directors of MusclePharm Corporation (the “Company”), effective immediately. Mr. Jenkins’ resignation was not as a result of a disagreement or dispute with the Company.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MUSCLEPHARM  
CORPORATION**

By: /s/ Peter C. Lynch  
Name: Peter C.  
Lynch  
Title: Chief  
Financial Officer

Date: December 19, 2016